- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...

Apertura has licensed its novel TfR1 capsid (TfR1 CapX) to partners targeting CNS disorders TfR1 CapX enables broad brain distribution via intravenous dosing, meeting the urgent need for a ...

CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...

Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology Additional Predictive, Analytic and Descriptive ...

TTUHSC’s Quentin R. Smith, Ph.D., and a team of researchers investigated methods to accurately measure drug permeability across the blood-brain barrier. For decades, scientists across the globe have ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...

Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme (GBM) for ...

The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on September 8, 2017 that brought together key experts from academia, government, the biotechnology and pharmaceutical ...

The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...

The MarketWatch News Department was not involved in the creation of this content. -- CANDID-CNS(TM) is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small ...